Firefly Neuroscience's Versus Platform Now Commercially Available For EEG Testing

Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an artificial intelligence ("AI") company advancing precision neuroscience and non-invasive brain-computer interface (BCI) technology, today provided an update on its non-invasive brain-computer interface ("BCI") strategy, highlighting the role of its commercially available Versus platform in pursuing the human-performance market.

Building on the Versus commercial launch, Firefly is outlining how the platform fits within its broader strategy to translate brain signals into practical applications across brain health and human performance. Versus combines a wireless EEG headset with interactive training software, enabling users to control simulation and other apps through real-time brainwave activity.